Search results
Results from the WOW.Com Content Network
In these studies, ceftolozane–tazobactam was notable for its activity against Pseudomonas aeruginosa, a common cause of hospital-acquired infections that is commonly multi-drug resistant. Ninety percent of Pseudomonas aeruginosa isolates were inhibited by a ceftolozane–tazobactam at a concentration of 4 μg/mL ( MIC 90 ), making it the most ...
The activity of ceftazidime/avibactam against the important hospital pathogen Pseudomonas aeruginosa is variable, due to the potential presence of other resistance mechanisms in addition to β-lactamase production.
Pseudomonas is a genus of Gram-negative bacteria belonging to the family Pseudomonadaceae in the class Gammaproteobacteria.The 348 members of the genus [2] [3] demonstrate a great deal of metabolic diversity and consequently are able to colonize a wide range of niches and hosts.
Pseudomonas can, in rare circumstances, cause community-acquired pneumonias, [39] as well as ventilator-associated pneumonias, being one of the most common agents isolated in several studies. [40] Pyocyanin is a virulence factor of the bacteria and has been known to cause death in C. elegans by oxidative stress .
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Avibactam is a non-β-lactam β-lactamase inhibitor [2] developed by Actavis (now Teva) jointly with AstraZeneca.A new drug application for avibactam in combination with ceftazidime was approved by the FDA in 2015 for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic-resistant pathogens, including those caused by multidrug ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx ...